Healthcare

https://techpapersworld.com/wp-content/uploads/2024/10/NUCLIDIUM-Announces-First-Patient-Imaged-in-1280x720.jpg

HealthcareNUCLIDIUM Announces First Patient Imaged in Phase 1 Study Evaluating 61Cu-based Radiotracer in Patients with PSMA-positive Prostate Cancer

NUCLIDIUM today announced that the first patient has been successfully imaged in a phase 1 clinical trial evaluating the company’s radiotracer candidate as a safe and accurate diagnostic and disease-staging imaging agent in prostate cancer patients. 61Cu-NuriProTM (61Cu-NODAGA-PSMA I&T) is the diagnostic component of NUCLIDIUM’s NuriProTM program, binding specifically to Prostate Specific Membrane Antigen (PSMA). PSMA has evolved as an established biomarker for the diagnosis, staging, and treatment of patients suffering from certain types of prostate cancer.1,2,3,4 61Cu-NuriPro is the...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/10/Evosep-Expanding-Capabilities--1280x720.jpg

HealthcareEvosep Expanding Capabilities with New Headquarters to Support Rising Needs in Pharma and Biotech for Proteomics

Evosep, a global leader in proteomics solutions, is proud to announce its relocation to new headquarters in Odense. This move will significantly enhance the company’s ability to advance the use of proteomics as a vital tool for the pharmaceutical and biotech industries. Building on recent strategic initiatives, the new facility will serve as a hub for continued innovation, reinforcing Evosep’s commitment to improving drug discovery, development, and diagnostics through high-precision proteomics. The decision to relocate is...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/10/Keio-University-Research-Genomic-1-3-1280x720.jpg

HealthcareKeio University Research: Genomic Insights for Personalized Cancer Treatment

n a recent paper published in Cancer Discovery, Keio University’s Sara Horie and her colleagues conducted an in-depth analysis of cancer driver alterations using genomic data from Japanese and international cohorts. The study elucidates the genomic landscape of Japanese patients and identifies significant genomic differences between Asian and white populations, providing valuable resources for cancer genomic medicine. These findings have important implications for appropriate patient selection in molecularly targeted therapies. Background The advent of next-generation sequencing (NGS) has transformed...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/10/Chiesi-launches-innovation-platform-1280x720.jpg

HealthcareChiesi launches innovation platform focused on partnership and patient care: The Impulse

Chiesi Group, a research-oriented international biopharmaceutical group, is proud to announce the official launch of The Impulse, an innovation platform designed to accelerate bold ideas and meaningful partnerships in healthcare. The Impulse aims to tackle some of the biggest challenges facing patients, planet, and people today by addressing not only healthcare symptoms but also the root causes of these challenges, such as climate change and access to care. Empowering innovation through collaboration The Impulse is...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/10/ACHC-INVESTOR-NOTICE-Robbins-Geller-Rudman-1280x720.jpg

HealthcareACHC INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Acadia Healthcare Company, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Acadia Healthcare Company, Inc. (NASDAQ: ACHC) publicly traded securities between February 28, 2020 and September 26, 2024, inclusive (the “Class Period”), have until December 16, 2024 to seek appointment as lead plaintiff of the Acadia Healthcare class action lawsuit. Captioned Kachrodia v. Acadia Healthcare Company, Inc., No. 24-cv-01238 (M.D. Tenn.), the Acadia Healthcare class action lawsuit charges Acadia Healthcare and certain of Acadia Healthcare’s top current...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/10/Etcembly-and-University-of-Surrey-Launch-Pioneering.jpg

HealthcareEtcembly and University of Surrey Launch Pioneering Study to Unlock Next-Generation Cancer Treatments From Survivors

British techbio innovator Etcembly is teaming up with researchers and clinicians from the University of Surrey to launch a groundbreaking new study that could transform the future of cancer treatment. By analysing the immune cells of cancer survivors, this research is set to reveal untapped targets that could deliver the next generation of immunotherapies. “By studying people who are surviving cancer, we can identify targets that have already proven to be effective, giving us a blueprint to develop a...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/10/EmeTerm-Smart-and-HeadaTerm-Copy-1280x720.jpg

HealthcareEmeTerm Smart and HeadaTerm 2 Achieve Health Canada MDL Certification

WAT Medical Enterprise proudly announces a significant achievement: both EmeTerm Smart and HeadaTerm 2 have received Medical Device Licences (MDL) from Health Canada. EmeTerm Smart was certified on August 12, 2024, followed by HeadaTerm 2 on September 25, 2024. This milestone underscores WAT Medical’s commitment to innovation and excellence in healthcare solutions, particularly as the demand for effective treatments grows alongside advancements in autonomous driving and self-driving technologies, such as Tesla’s Cybercab and other robotaxi services. WAT...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/09/NUS-researchers-develop-revolutionary-1280x720.jpg

HealthcareNUS researchers develop revolutionary technology to unravel complex protein interactions that could transform cancer diagnostics

A team of researchers from the National University of Singapore’s (NUS) Institute for Health Innovation & Technology (iHealthtech), led by Associate Professor Shao Huilin and Associate Professor Brian Lim, has developed a first-of-its-kind technology to map out diverse protein interactions in cells using DNA barcodes. The technology, dubbed TETRIS, can explicitly identify and quantify multiple interacting partners in large protein assemblies. By capturing the complex hierarchy of protein interactions within tumour cells, the technology uncovers detailed molecular mechanisms driving disease...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/09/Epic-calls-on-Particle-Health-1280x720.jpg

HealthcareEpic calls on Particle Health to approve release of resolution in patient privacy dispute

Epic and our customers protect the privacy of many Americans’ health data. At the direction of our customer governing council, we filed a dispute through the Carequality interoperability network against Particle Health because some Particle customers used the network to take people’s medical records under false pretenses. For example, a business, Integritort, claimed to be treating patients when in fact it was gathering medical records for personal injury law firms to review for potential class...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/09/AIRAmed-and-Memory-Treatment-Centers-Bonita-Springs-1280x720.jpg

HealthcareAIRAmed and Memory Treatment Centers (Bonita Springs and Jacksonville, Florida) have launched a research partnership aimed at studying Alzheimer’s disease in cognitively impaired individuals undergoing anti-amyloid therapy

AIRAmed, a software company dedicated to the earlier detection of neurodegenerative diseases, more precise diagnoses, personalized treatments, and improving the quality of life for affected patients, is pleased to announce a research collaboration with Memory Treatment Centers. In partnership with Dr. Donald McCarren (DO, FAAN, FAANEM), Dr. Samuel Giles (MD), Dr. Robert Mannel (MD) and Dr. Jamie Plante (MD), the study will focus on quantitative brain volume measurements in cognitively impaired individuals receiving anti-amyloid treatment. Dr Tobias Lindig, Managing Director, AIRAmed said, “AIRAmed’s vision...

Newer Posts

Older Posts